Table 4.
Multivariable analysis of uterine sarcoma patients reporting crude (cHR) and adjusted hazard ratios (aHR) with a 95% Confidence Interval (CI)
| Characteristic | cHR (95% CI) | p-value | aHR (95% CI) | p-value |
|---|---|---|---|---|
| Age (years) | ||||
| < 50 | 1 | |||
| ≥ 50 | 1.41 (1.16–2.78) | 0.176* | 1.36 (0.56–3.40) | 0.091 |
| Menstrual status | ||||
| Pre-menstrual | 1 | |||
| Post-menstrual | 1.23 (1.09–2.63) | 0.081* | 1.11 (0.67–2.99) | 0.079 |
| Parity | ||||
| Parity = 0 | 1 | |||
| Parity ≥ 1 | 1.76 (0.57–4.07) | 0.300 | - | - |
| Tumor size | ||||
| < 5 cm | 1 | |||
| ≥ 5 cm | 1.95 (1.07–4.20) | 0.020* | 1.91 (1.39–2.82) | 0.047** |
| Figo stage | ||||
| Stage I | 1 | |||
| Stage II | 3.43 (2.46–5.51) | 2.51 (1.20–3.51) | ||
| Stage III | 4.55 (2.90–7.52) | 0.002* | 2.94 (1.43–4.07) | 0.015** |
| Stage IV | 4.24 (2.87–7.38) | 2.81 (1.37–3.90) | ||
| Grade of tumor | ||||
| Well | 1 | |||
| Moderate | 1.80 (1.12–3.56) | 0.044 | - | - |
| Poor | 2.50 (1.91–5.33) | |||
| LVI | ||||
| Negative | 1 | |||
| Positive | 0.61 (0.26–1.44) | 0.273 | - | - |
| Mitotic index | ||||
| < 15 per HPF | 1 | 1 | ||
| > 15 per HPF | 1.58 (1.16–3.63) | 0.084* | 1.49 (0.97–2.39) | 0.052 |
| Lymph node status | ||||
| Negative | 1 | |||
| Positive | 2.81 (0.89–6.81) | 0.389 | - | - |
*Significant level on univariate analysis
**Significant level on multivariate analysis